Company intelligence / Profile preview

NitroSci

West Allis, Wisconsin, United States

Ownership: Private
Development stage: Other

Overview

NitroSci is developing non-toxic, cost-effective magnetic resonance imaging (MRI) contrast agents using stable nitroxide free radicals. Its primary product is designed to monitor the progression of osteoarthritis by targeting cartilage glycosaminoglycans.

Therapeutic areas: CardiovascularRheumatology
Modalities: Small molecule
Industry: Medical Imaging

Beyond the preview

Go deeper on NitroSci.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NitroSci.

Explore the full profile